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persistent symptoms. We investigate, in a sample of 10,363 UK adults aged 16-98, modification by antidepressants of cross-sectional and longitudinal associations between C-reactive protein and psychological distress (General Health Questionnaire score, GHQ). We account for confounding by age, gender, income, inflammatory somatic illness, body mass index and, in longitudinal models, baseline psychological distress. Sensitivity analyses consider smoking, ethnicity, and other medications.
Results
Robust associations of log-CRP and GHQ were seen for antidepressant users but not for non-users in both cross-sectional (coeff:0.54, p=0.01 vs 0.06, p=0.28) and longitudinal models (coeff: 0.57, p=0.006 vs 0.04, p=0.39 two waves post-baseline). Cross-sectional associations were strongest for tricyclic users, and longitudinal associations strongest for SSRI users. In multilevel, repeatedmeasures longitudinal models, associations for antidepressant users peaked two waves after baseline before declining.
Conclusions
Results suggest evidence for existence of an inflammatory depression subtype. Previous studies' exclusion of antidepressant users and failure to consider interactive effects may have obscured associations driven by the subgroup. Follow-up work is now needed in community samples with clinical depression measures and prescription histories, to further elucidate the mechanisms involved.
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Background
Clinical evidence increasingly suggests inflammation may be important specifically for an etiologically distinct depression subtype, characterized by resistance to antidepressant medication.
However, epidemiological investigations of the relationship of inflammation with depression and psychological distress have failed to acknowledge these developments, which may have resulted in bias or masking of associations driven by the subtype. This may have contributed to inconsistent results in epidemiological studies, and equivocal support for an inflammation-depression link.
Methods
An antidepressant-resistant, inflammatory depression subtype would result in stronger associations of depressive symptomatology with inflammation among antidepressant users than non-users, due to over-representation of subtype individuals among antidepressant users experiencing severe or persistent symptoms. We investigate, in a sample of 10,363 UK adults aged 16-98, modification by antidepressants of cross-sectional and longitudinal associations between C-reactive protein and psychological distress (General Health Questionnaire score, GHQ). We account for confounding by age, gender, income, inflammatory somatic illness, body mass index and, in longitudinal models, baseline psychological distress. Sensitivity analyses consider smoking, ethnicity, and other medications.
Results
Robust associations of log-CRP and GHQ were seen for antidepressant users but not for non-users in both cross-sectional (coeff:0.54, p=0.01 vs 0.06, p=0.28) and longitudinal models (coeff: 0.57, p=0.006 vs 0.04, p=0.39 two waves post-baseline). Cross-sectional associations were strongest for Introduction Depression-like symptoms are produced by acute elevations in inflammatory activity, either as part of 'sickness behaviour' following infection or injury, or by experimentally-induced responses to exogenous inflammatory agents (Miller, Maletic et al. 2009 ). The inflammatory theory of depression argues that, similarly, depressive symptoms and syndromes are linked to variations in endogenous 'systemic' inflammation, a milder analogue of the acute inflammatory response which occurs in the absence of infection or injury. In large community samples this has been investigated by examining associations of circulating inflammatory markers with depression diagnoses or questionnairederived psychological distress, concurrently or after a follow-up period. However, both crosssectional (Dowlati, Herrmann et al. 2010; de Menezes, de Figueiredo et al. 2017 ) and longitudinal community studies (Valkanova, Ebmeier et al. 2013; Chocano-Bedoya, Mirzaei et al. 2014; Au, Smith et al. 2015; Das 2016 ) are equivocal in their support for an impact of inflammation on depressive symptomatology. Heterogeneity in results may partly relate to modifying factors such as age, gender and follow-up time (Das 2016; Engler, Benson et al. 2016) , but clinical work increasingly suggests systemic inflammation is important specifically for an etiologically distinct depressive subtype, characterised by poor antidepressant treatment response (Barnes, MondeIli et al. 2017) . Nonresponse to antidepressants is predicted by circulating inflammatory markers (Eller, Vasar et al. 2008) , gene variants associated with elevated inflammation (Baune, Dannlowski et al. 2010 ) and transcription of genes in the inflammatory cytokine pathway (Powell, Schalkwyk et al. 2013) , while administration of anti-inflammatory agents improves treatment response (Raison, Rutherford et al. 2013 ). Thus, in epidemiological studies, mixed findings may relate to failure to consider a distinct inflammatory-depressive 'immunophenotype', which may obscure associations (Barnes, MondeIli et al. 2017 ). Meanwhile, antidepressants may partly work via anti-inflammatory actions, since they appear to have anti-inflammatory effects peripherally and within the brain (Tynan, Weidenhofer et al. 2012 ), but certain antidepressants may promote inflammation, with cross-sectional CRP elevations net of depressive symptoms reported for tricyclics, tetracyclics, and serotoninnorepinephrine reuptake inhibitors, but not SSRIs (Hamer, Batty et al. 2011; Vogelzangs, Duivis et al. 2012) .
The relationship between inflammation, depressive symptomatology and antidepressants is therefore complex, possibly modified further by antidepressant type. If an inflammatory-depressive subtype exists characterised by poor antidepressant response, in an observational study we should expect a stronger inflammation-depression relationship among antidepressant users compared to non-users, since individuals with inflammatory depression will be over-represented among users reporting severe or persistent symptoms. If antidepressants work via anti-inflammatory effects, we should expect a weaker relationship among users, as variation at the high end of the range for both inflammatory markers and depressive symptoms are reduced together, relative to depressed but medically untreated individuals. If certain antidepressants raise inflammatory markers while reducing depressive symptoms, we should expect weaker inflammation-depression links among users of those antidepressants specifically.
Epidemiological studies typically exclude antidepressant users (Camacho, Larsen et al. 2014; Zalli, Jovanova et al. 2016) , or adjust for antidepressants (Gimeno, Kivimaki et al. 2009; Das 2016) . If antidepressant use modifies associations, exclusion will produce biased estimates, while adjustment without subgroup analysis may obscure associations concentrated in a small treatment-resistant subgroup. To our knowledge only one study has considered antidepressant modification, reporting a cross-sectional association of the inflammatory marker C-reactive protein (CRP) with somatic (but not cognitive) depressive symptoms restricted to non-users of antidepressants. The authors suggest this supports anti-inflammatory effects of antidepressants (White, Kivimäki et al. 2016) , but since participants with CRP values suggesting current infection were not excluded, associations may also reflect infection-related sickness behaviour, statistically detectable only in the larger group.
We integrate the hypothesis of the antidepressant-resistant, inflammatory depression subtype into an epidemiological study. We investigate modification of cross-sectional and longitudinal associations of CRP with General Health Questionnaire score, a measure of psychological distress, by all antidepressants, and by antidepressant types.
Methods
The UKHLS is an annual longitudinal survey of over UK 40,000 households, comprising a larger General Population Sample (GPS), a stratified clustered random sample of households representative of the UK population which joined in 2009-10, and a smaller component from the pre-existing British Household Panel Survey (BHPS) (Benzeval M., Davillas et al. 2014 ).
Sociodemographic information was obtained at annual interviews, and biomedical measures taken during a nurse visit five months after the wave 2 interview (W2, GPS participants) or wave 3 interview (W3, BHPS participants). Respondents were eligible for a biomedical visit if they took part in the corresponding main interview in English, were aged 16+, lived in England, Wales or Scotland, and were not pregnant. Of these 35875, 57.5% took part.
The initial sample was defined as participants present at the biomedical assessment and at least one subsequent wave. Participants were excluded if they had CRP>10mg/L, usually assumed to reflect current infection (Pearson, Mensah et al. 2003) . Of these 19,107, 11767 (61.6%) had usable CRP measurements, with missingness largely due to non-consent for blood sampling. 348 were excluded for lacking any follow-up GHQ measurements, and 1,056 for missing covariates, leaving 10,363.
Measures CRP was analyzed from serum using the N Latex CRP mono Immunoassay on the Behring Nephelometer II Analyzer (Benzeval M., Davillas et al. 2014) . Psychological distress was measured using the 12-item General Health Questionnaire (GHQ) (Goldberg, Gater et al. 1997 ). Participants were asked 12 questions to capture depressive and anxiety symptoms in the past four weeks, and an overall score (range 0-36) calculated.
All antidepressants with BNF codes 04.01.01-04.01.04 were considered, namely tricyclics, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and 'other' antidepressants (section 04.01.04). 958 participants were taking antidepressants, most commonly SSRIs (551 participants) followed by tricyclics (303 participants). 11 were taking MAOIs and 151 other antidepressants. 57 participants were taking two, usually a tricyclic plus SSRI (N=38).
All models adjusted for age and gender at biomedical assessment, and age-band specific quartiles of equivalised household income from W2/W3. Diagnoses at baseline of inflammatory somatic illness (asthma, emphysema, chronic bronchitis, cancer, cardiac problems including high blood pressure) were derived using questionnaire information from UKHLS W1/W2 (GPS participants) or BHPS W18
and UKHLS W2 (BHPS participants). Full-adjusted longitudinal models also included baseline GHQ score and diagnoses of somatic conditions during follow-up, again using annual questionnaire information. Baseline BMI was calculated from height and weight measured by a nurse using a portable stadiometer and Tanita-BF522 digital floor scales, and classified as <18.5, 18.5-24.9, 25.0-29.9, and ≥30. Anti-inflammatory medications included non-steroidal anti-inflammatory medications (NSAIDs), statins, and corticosteroids.
Analysis GHQ scores approximated a normal distribution so were included untransformed in linear regressions; CRP was skewed and therefore log-transformed. Relationships were examined separately by antidepressant use: non-users, all antidepressants, SSRIs, tricyclics, MAOIs and others, combined treatment. To construct trajectories of CRP-GHQ associations, GHQ scores 1, 2 and 3 waves post-baseline were modelled as functions of baseline log-CRP, using an interaction term between log-CRP and waves since baseline. A repeated-measures, multilevel panel data structure was used, with measurements 1, 2 and 3 waves later nested within individuals. Baseline covariates including baseline GHQ were treated as time-invariant, and new diagnoses during follow-up as timevarying. Unbalanced data was allowed, meaning participants were included even if not present at all outcome waves. All analyses used robust standard errors to account for survey effects.
Antidepressant use was considerably more common among female participants, and related to GHQ score. Thus, to ascertain whether antidepressant use itself modified associations, we explored gender interaction, and reran models restricted to participants with clinically relevant GHQ scores following Goldberg (Goldberg, Gater et al. 1997 ), using both the ≥3 and ≥4 cutoffs from 0-12 scoring.
Further sensitivity analyses adjusted for anti-inflammatory medications, time of day, season, and processing time of blood samples, and for smoking, which may be a cause or consequence of psychological distress (Taylor, Fluharty et al. 2014) . A sensitivity analysis exploring impact of ethnicity excluded the 3.7% of participants defining not as a white group, while another excluded women taking oral contraceptives (OCs) or hormone replacement therapy (HRT).
Results
Compared to non-users, antidepressant users were slightly older, less affluent and considerably more likely to be female. They were more likely to be white, current or former smokers, and to have extreme BMIs (underweight or obese). They were more likely to take anti-inflammatory medications, OCs or HRT, and have a relevant somatic illness. They had higher CRP and higher GHQ scores at all waves (all p<0.05).
In cross-sectional models adjusted for age, gender and household income (Table 2) , CRP was associated with GHQ for all participants. For non-users of antidepressants, adjustment for BMI and long-term illness explained associations. Conversely, a GHQ elevation for antidepressant users was robust (coeff: 0.54, p=0.01) and strongest for tricyclic users (coeff: 1.07, p=0.006). No significant associations were seen for other antidepressant types. There was no significant CRP-GHQ association for participants not taking antidepressants with clinically significant GHQ symptoms using either the lower or the higher threshold (respectively, N=1,816, coeff: 0.04, p=0.76; N=1,423, coeff:-0.02, CI:-0.28-0.24, p=0.88). In a whole-sample model, an interaction term for CRP*gender suggested a weaker CRP-GHQ association for women, but was non-significant (coeff=-0.18, p=0.08).
Adjustment for smoking made little difference (0.49, p=0.02 for all antidepressant users; 1.01, p=0.01 for tricyclics), as did adjustment for anti-inflammatory medications (0.53, p=0.001 for all antidepressants, 1.06, p=0.007 for tricyclics), or time of day, season and processing time of blood samples (0.53, p=0.01 for all antidepressants; 1.06, p=0.007 for tricyclics), excluding nonwhite/mixed participants (for all antidepressants, 0.58, p=0.007; for tricyclics, 1.10, p=0.005), or excluding women taking OCs/HRT (for all antidepressants, 0.52, p=0.02, for tricyclics, 1.05, p=0.01). 
Longitudinal
In longitudinal models adjusted for baseline GHQ, age, gender, household income, a modest association emerged across the three years for non-users of antidepressants (coeff: 0.12, p=0.02 at the third outcome point), which was explained by addition of BMI and long-term illness. Among users, there was no association one or three waves post-baseline, but a sharp peak in associations after two waves, robust to adjustment for BMI and illness (coeff: 0.57, p=0.006). This was strongest for SSRI users (fully-adjusted coeff=0.77, p=0.008), and the small group using multiple antidepressants, although estimates for that group were imprecise (fully-adjusted coeff=1.61, p=0.15). The elevation was not explained by gender interaction (for men and women, elevations were 0.09, p=0.20 and 0.13, 0.06 respectively; interaction p=0.65). Trajectories of GHQ 1, 2 and 3 waves post-baseline indicate that the longitudinal relationship of CRP and psychological distress is also substantially modified by antidepressant use, in particular SSRIs, for which predictive effects of inflammatory activity on treatment response are well documented.
Among non-users of antidepressants, that a modest emergent association across the three-year outcome period was largely explained by BMI and chronic illness may reflect confounding by these factors, or that adiposity and chronic illness are key upstream drivers of systemic inflammation which in turn leads to psychological distress.
The increase for antidepressant users in associations at year 2 is difficult to explain. Since we have no information on antidepressant use post-baseline, this may relate to treatment secession, changes in antidepressant dosage or type, or further deterioration in responsiveness. Similarly, decreased associations at year 3 could reflect improved symptom management by pharmaceutical or other means, or baseline inflammation becoming, over time, an increasingly weak proxy of current inflammation.
Strengths and limitations
Unlike previous studies, we used data from a nationally-representative sample across the whole adult age range, considered modification by several types of antidepressants, and investigated evolution of associations across a three-year outcome period. However, the GHQ measures psychological distress, and associations with diagnosed depression may differ. We do not know prescription histories or why particular antidepressants were prescribed, limiting the conclusions which can be drawn.
Conclusion
This study finds a substantially stronger relationship among antidepressant users than non-users of an inflammatory marker with psychological distress. Cross-sectional observations were strongest for tricyclic users, and longitudinal associations by SSRI users, indicating the mechanisms involved may be sensitive to antidepressant type. Results indicate that researchers should be careful to treat antidepressant use appropriately in epidemiological studies of the inflammation-depression link, and may support existence of an aetiologically distinct, antidepressant-resistant, inflammatory depression subtype. Further work in community samples considering diagnosed depression and prescription histories is now needed to elucidate the mechanisms involved.
